GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,805.00p
   
  • Change Today:
    -11.50p
  • 52 Week High: 1,901.50
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,075.43m
  • Volume: 1,609,818
  • Market Cap: £73,561m
  • RiskGrade: 129
  • Beta: 0.94

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book n/a  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 34,099.00 6,968.00 115.90p 14.5 n/a -6% 80.00p 4.8%
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 34,111.43 9,727.76 181.43p 10.0 1.1 +9% 69.65p 0.0%
31-Dec-27 35,722.20 10,525.40 196.17p 9.3 1.1 +8% 74.15p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Director/PDMR Shareholding 16-Jan-2026 15:30 RNS
Director/PDMR Shareholding 15-Jan-2026 15:30 RNS
Director/PDMR Shareholding 13-Jan-2026 15:30 RNS

GSK ShareCast News

GSK chronic hepatitis B treatment hits goal in t... 07-Jan-2026 ShareCast
Japan approves GSK treatment for severe asthma 06-Jan-2026 ShareCast
GSK's COPD treatment approved by Chinese regulat... 05-Jan-2026 ShareCast

GSK Top Newspaper Links

GSK’s hepatitis B drug shows promise in trials 07-Jan-2026 Times
GlaxoSmithKline scraps sale of old drugs 05-Dec-2014 Telegraph
Glaxo sharpens axe to save £1bn as insurers and ... 01-Dec-2014 The Independent

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
14-Jan-26 Buy Dividends Hal Barron 1,871.05p 5,664 £105,976.17
08-Jan-26 Buy Dividends Luke Miels 1,894.33p 3 £56.83
22-Dec-25 Buy Jonathan Symonds 1,810.46p 1,650 £29,872.59

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,805.00p
Change Today -11.50p
% Change -0.63 %
52 Week High 1,901.50
52 Week Low 1,264.00
Volume 1,609,818
Shares Issued 4,075.43m
Market Cap £73,561m
Beta 0.94
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average6.98% above the market average
36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average36.36% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 13
Sell 3
Strong Sell 0
Total 23
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q3 Q2
Ex-Div 13-Nov-25 14-Aug-25
Paid 08-Jan-26 09-Oct-25
Amount 16.00p 16.00p

Trades for 19-Jan-2026

Time Volume / Share Price
13:40 0 @ 1,805.50p
13:40 33 @ 1,805.50p
13:40 1 @ 1,805.00p
13:40 708 @ 1,805.00p
13:40 0 @ 1,805.50p

GSK Key Personnel

CEO Luke Miels

Top of Page